Compare PMT & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMT | ARDX |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2014 |
| Metric | PMT | ARDX |
|---|---|---|
| Price | $12.12 | $7.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $13.50 | ★ $15.14 |
| AVG Volume (30 Days) | 1.1M | ★ 3.5M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 13.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | N/A | $37.75 |
| Revenue Next Year | $1.55 | $34.24 |
| P/E Ratio | $12.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.15 | $3.50 |
| 52 Week High | $13.80 | $8.40 |
| Indicator | PMT | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 75.50 |
| Support Level | $11.72 | $6.83 |
| Resistance Level | $12.15 | $8.05 |
| Average True Range (ATR) | 0.22 | 0.33 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 58.62 | 95.03 |
PennyMac Mortgage Investment Trust is a specialty finance company that invests primarily in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.